1. Neuroscience

The cytokine GDF15 signals through a population of brainstem cholecystokinin neurons to mediate anorectic signalling

  1. Amy A Worth
  2. Rosemary Shoop
  3. Katie Tye
  4. Claire H Feetham
  5. Giuseppe D'Agostino
  6. Garron T Dodd
  7. Frank Reimann
  8. Fiona M Gribble
  9. Emily C Beebe
  10. James D Dunbar
  11. Jesline T Alexander-Chacko
  12. Dana K Sindelar
  13. Tamer Coskun
  14. Paul J Emmerson
  15. Simon M Luckman  Is a corresponding author
  1. University of Manchester, United Kingdom
  2. University of Melbourne, Australia
  3. University of Cambridge, United Kingdom
  4. Eli Lilly and Company, United States
https://doi.org/10.7554/eLife.55164
Share this article
Cite this article
  1. Amy A Worth
  2. Rosemary Shoop
  3. Katie Tye
  4. Claire H Feetham
  5. Giuseppe D'Agostino
  6. Garron T Dodd
  7. Frank Reimann
  8. Fiona M Gribble
  9. Emily C Beebe
  10. James D Dunbar
  11. Jesline T Alexander-Chacko
  12. Dana K Sindelar
  13. Tamer Coskun
  14. Paul J Emmerson
  15. Simon M Luckman
(2020)
The cytokine GDF15 signals through a population of brainstem cholecystokinin neurons to mediate anorectic signalling
eLife 9:e55164.
https://doi.org/10.7554/eLife.55164
  2. Download BibTeX
  3. Download .RIS

Abstract

The cytokine, GDF15, is produced in pathological states which cause cellular stress, including cancer. When over expressed, it causes dramatic weight reduction, suggesting a role in disease-related anorexia. Here we demonstrate that the GDF15 receptor, GFRAL, is located in a subset of cholecystokinin neurons which span the area postrema and the nucleus of the tractus solitarius of the mouse. GDF15 activates GFRALAP/NTS neurons and supports conditioned taste and place aversions, while the anorexia it causes can be blocked by a monoclonal antibody directed at GFRAL or by disrupting CCK neuronal signalling. The cancer-therapeutic drug, cisplatin, induces the release of GDF15 and activates GFRALAP/NTS neurons, as well as causing significant reductions in food intake and body weight in mice. These metabolic effects of cisplatin are abolished by pre-treatment with the GFRAL monoclonal antibody. Our results suggest that GFRAL neutralising antibodies or antagonists may provide a co-treatment opportunity for patients undergoing chemotherapy.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Amy A Worth

    Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.

  2. Rosemary Shoop

    Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3617-4358

  3. Katie Tye

    Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.

  4. Claire H Feetham

    Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.

  5. Giuseppe D'Agostino

    Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.

  6. Garron T Dodd

    Department of Physiology, University of Melbourne, Melbourne, Australia
    Competing interests
    No competing interests declared.

  7. Frank Reimann

    Wellcome Trust MRC Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    No competing interests declared.

  8. Fiona M Gribble

    Wellcome Trust MRC Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    No competing interests declared.

  9. Emily C Beebe

    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, United States
    Competing interests
    Emily C Beebe, Paid employee of Eli Lilly..

  10. James D Dunbar

    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, United States
    Competing interests
    James D Dunbar, Paid employee of Eli Lilly..

  11. Jesline T Alexander-Chacko

    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, United States
    Competing interests
    Jesline T Alexander-Chacko, Paid employee of Eli Lilly..

  12. Dana K Sindelar

    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, United States
    Competing interests
    Dana K Sindelar, Paid employee of Eli Lilly..

  13. Tamer Coskun

    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, United States
    Competing interests
    Tamer Coskun, Paid employee of Eli Lilly..

  14. Paul J Emmerson

    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, United States
    Competing interests
    Paul J Emmerson, Paid employee of Eli Lilly..

  15. Simon M Luckman

    Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    For correspondence
    simon.luckman@manchester.ac.uk
    Competing interests
    Simon M Luckman, BB/S008098/1 is a BBSRC Industrial Partnership Award between SML and Eli Lilly.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5318-5473

Funding

Biotechnology and Biological Sciences Research Council (BB/M001067/1)

  • Simon M Luckman

Biotechnology and Biological Sciences Research Council (BB/L021129/1)

  • Simon M Luckman

Medical Research Council (MR/R002991/1)

  • Simon M Luckman

Medical Research Council (MR/P009824/2)

  • Giuseppe D'Agostino

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All procedures were conducted in accordance with either: the United Kingdom Animals (Scientific Procedures) Act, 1986 (ASPA) and approved by the local animal welfare ethical review body (AWERB); the Eli Lilly Institutional Animal Care and Use Committee (IACUC) in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals; or the University of Melbourne Animal Ethics Committee (1914919) and conformed to National Health & 8 Medical Research Council (Australia) guidelines regarding the care and use of experimental animals. Additional guidance from the UK National Centre for 3R's (NC3Rs) was followed where applicable.

Copyright

© 2020, Worth et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,365
    views
  • 701
    downloads
  • 63
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Amy A Worth
  2. Rosemary Shoop
  3. Katie Tye
  4. Claire H Feetham
  5. Giuseppe D'Agostino
  6. Garron T Dodd
  7. Frank Reimann
  8. Fiona M Gribble
  9. Emily C Beebe
  10. James D Dunbar
  11. Jesline T Alexander-Chacko
  12. Dana K Sindelar
  13. Tamer Coskun
  14. Paul J Emmerson
  15. Simon M Luckman
(2020)
The cytokine GDF15 signals through a population of brainstem cholecystokinin neurons to mediate anorectic signalling
eLife 9:e55164.
https://doi.org/10.7554/eLife.55164

Share this article

https://doi.org/10.7554/eLife.55164

Categories and tags

Research organisms

Further reading

    1. Neuroscience

    Parabrachial CGRP neurons modulate active defensive behavior under a naturalistic threat

    Gyeong Hee Pyeon, Hyewon Cho ... Yong Sang Jo
    Research Article Updated

    Recent studies suggest that calcitonin gene-related peptide (CGRP) neurons in the parabrachial nucleus (PBN) represent aversive information and signal a general alarm to the forebrain. If CGRP neurons serve as a true general alarm, their activation would modulate both passive nad active defensive behaviors depending on the magnitude and context of the threat. However, most prior research has focused on the role of CGRP neurons in passive freezing responses, with limited exploration of their involvement in active defensive behaviors. To address this, we examined the role of CGRP neurons in active defensive behavior using a predator-like robot programmed to chase mice. Our electrophysiological results revealed that CGRP neurons encode the intensity of aversive stimuli through variations in firing durations and amplitudes. Optogenetic activation of CGRP neurons during robot chasing elevated flight responses in both conditioning and retention tests, presumably by amplifying the perception of the threat as more imminent and dangerous. In contrast, animals with inactivated CGRP neurons exhibited reduced flight responses, even when the robot was programmed to appear highly threatening during conditioning. These findings expand the understanding of CGRP neurons in the PBN as a critical alarm system, capable of dynamically regulating active defensive behaviors by amplifying threat perception, and ensuring adaptive responses to varying levels of danger.

    1. Evolutionary Biology
    2. Neuroscience

    Vision: The inner workings of a miniature eye

    Gregor Belušič
    Insight

    The first complete 3D reconstruction of the compound eye of a minute wasp species sheds light on the nuts and bolts of size reduction.

    1. Neuroscience

    Disruption of the CRF1 receptor eliminates morphine-induced sociability deficits and firing of oxytocinergic neurons in male mice

    Alessandro Piccin, Anne-Emilie Allain ... Angelo Contarino
    Research Article

    Substance-induced social behavior deficits dramatically worsen the clinical outcome of substance use disorders; yet, the underlying mechanisms remain poorly understood. Herein, we investigated the role for the corticotropin-releasing factor receptor 1 (CRF1) in the acute sociability deficits induced by morphine and the related activity of oxytocin (OXY)- and arginine-vasopressin (AVP)-expressing neurons of the paraventricular nucleus of the hypothalamus (PVN). For this purpose, we used both the CRF1 receptor-preferring antagonist compound antalarmin and the genetic mouse model of CRF1 receptor-deficiency. Antalarmin completely abolished sociability deficits induced by morphine in male, but not in female, C57BL/6J mice. Accordingly, genetic CRF1 receptor-deficiency eliminated morphine-induced sociability deficits in male mice. Ex vivo electrophysiology studies showed that antalarmin also eliminated morphine-induced firing of PVN neurons in male, but not in female, C57BL/6J mice. Likewise, genetic CRF1 receptor-deficiency reduced morphine-induced firing of PVN neurons in a CRF1 gene expression-dependent manner. The electrophysiology results consistently mirrored the behavioral results, indicating a link between morphine-induced PVN activity and sociability deficits. Interestingly, in male mice antalarmin abolished morphine-induced firing in neurons co-expressing OXY and AVP, but not in neurons expressing only AVP. In contrast, in female mice antalarmin did not affect morphine-induced firing of neurons co-expressing OXY and AVP or only OXY, indicating a selective sex-specific role for the CRF1 receptor in opiate-induced PVN OXY activity. The present findings demonstrate a major, sex-linked, role for the CRF1 receptor in sociability deficits and related brain alterations induced by morphine, suggesting new therapeutic strategy for opiate use disorders.